Search research articles
Contact Us
Filters
Showing results (141-150 of 188) with videos related to
Page
of 19
Sort By:
British Journal of Cancer
|
May 19, 2018
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project
Giuseppe Gullo, Naomi Walsh, David Fennelly, et al.
Oncotarget
|
September 7, 2013
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Alexandra Canonici, Merel Gijsen, Maeve Mullooly, et al.
Breast Cancer Research and Treatment
|
June 19, 2010
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study
Janine L Mansi, Ann Yellowlees, Julian Lipscombe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
JAMA Oncology
|
December 7, 2018
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
Michael F Press, Jose A Seoane, Christina Curtis, et al.
The New England Journal of Medicine
|
December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E Geyer, John Forster, Deborah Lindquist, et al.
British Journal of Cancer
|
July 28, 2023
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
Nicola Gaynor, Alfonso Blanco, Stephen F Madden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2005
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study
T R Jeffry Evans, Ann Yellowlees, Elizabeth Foster, et al.
The Oncologist
|
August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials
Andrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 1, 2022
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
Xiaokai Ding, Amanda C Sharko, Martina S J McDermott, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 188) with videos related to
Sort By:
Page
of 19
British Journal of Cancer
|
May 19, 2018
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project
Giuseppe Gullo, Naomi Walsh, David Fennelly, et al.
Oncotarget
|
September 7, 2013
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Alexandra Canonici, Merel Gijsen, Maeve Mullooly, et al.
Breast Cancer Research and Treatment
|
June 19, 2010
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study
Janine L Mansi, Ann Yellowlees, Julian Lipscombe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
JAMA Oncology
|
December 7, 2018
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
Michael F Press, Jose A Seoane, Christina Curtis, et al.
The New England Journal of Medicine
|
December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E Geyer, John Forster, Deborah Lindquist, et al.
British Journal of Cancer
|
July 28, 2023
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
Nicola Gaynor, Alfonso Blanco, Stephen F Madden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2005
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study
T R Jeffry Evans, Ann Yellowlees, Elizabeth Foster, et al.
The Oncologist
|
August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials
Andrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 1, 2022
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
Xiaokai Ding, Amanda C Sharko, Martina S J McDermott, et al.
Page
of 19